Contrasting Oruka Therapeutics (ORKA) & The Competition

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka Therapeutics to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, dividends, analyst recommendations and profitability.

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by company insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Oruka Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oruka Therapeutics N/A -$5.34 million -4.44
Oruka Therapeutics Competitors $558.35 million $6.13 million -107.11

Oruka Therapeutics’ peers have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for Oruka Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics 0 0 6 2 3.25
Oruka Therapeutics Competitors 871 816 1357 23 2.17

Oruka Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 61.79%. As a group, “Diagnostic substances” companies have a potential upside of 41.98%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than its peers.

Risk and Volatility

Oruka Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.32, meaning that their average share price is 32% more volatile than the S&P 500.

Profitability

This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -20.18% -19.51%
Oruka Therapeutics Competitors -1,870.01% -41.71% -26.40%

Summary

Oruka Therapeutics beats its peers on 10 of the 13 factors compared.

About Oruka Therapeutics

(Get Free Report)

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.